Martin Hoenigl, ECCMID 2022: Phase 3 FURI study investigating oral ibrexafungerp for the treatment of patients with severe fungal infections
Ibrexafungerp is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. Dr Martin Hoenigl (Professor, Translational Mycology, Medical University of Graz, Austria) discusses the ongoing Phase III FURI study investigating oral ibrexafungerp for the treatment of patients with severe fungal infections who are either intolerant to standard antifungal therapy or experience refractory fungal infections despite treatment.
The presentation entitled: ‘Oral ibrexafungerp outcomes by fungal disease in patients from 4th interim analysis of a phase III open-label study (FURI)’ was presented at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), 23-26 May 2022.
- Could you give us a brief overview of the clinical burden of fungal pathogens and the unmet needs in their treatment?
- What is the rationale for the use of oral ibrexafungerp for the treatment of patients who are intolerant of or with fungal disease refractory to standard antifungal therapy?
- What were the aims, design and eligibility criteria of the FURI study?
- What have been the interim findings of this study?
- Which patients are most likely to benefit from ibrexafungerp treatment?
Disclosures: Martin Hoenigl receives grant/research support from Gilead, Scynexis, Pfizer, Astellas, MSD, Euroimmun, and F2G.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In Fungal Infections
Kayla Stover Hielscher, IDWeek 2022: Isavuconazole – a good treatment option for Candida species?
Isavuconazole is a once-daily antifungal, used to treat a wide array of fungal infections. In this touchINFECTIOUS DISEASES interview, we met with Prof. Kayla Stover Hielscher (University of Mississippi School of Pharmacy, Jackson, MS, USA) to discuss isavuconazole’s properties and the efficacy and safety compared to other treatment options. The abstract entitled: ‘This Drug for […]
Martin Hoenigl, IDWeek 2022: Candidemia prognosis and unmet needs in its treatment
Candidemia is the one of the most common form of invasive candidiasis, and in some countries the most common causes of bloodstream infections in hospitalized patients. In this touchINFECTIOUS DISEASES interview, we met with Dr Martin Hoenigl (Medical University of Graz, Austria) to discuss the prognosis of candidemia, the unmet needs in its treatment, and […]
Martin Hoenigl, IDWeek 2022: Guideline adherence predicts outcomes of candidemia in Europe
In this touchINFECTIOUS DISEASES interview, we met with Dr Martin Hoenigl (Medical University of Graz, Austria) to discuss ECMM Candida III Multinational European study, which collected data on epidemiology, risk factors, treatment, and outcomes of culture proven candidemia across Europe, to assess how adherence to guideline recommendations correlate with outcomes. The abstract entitled: ‘Guideline Adherence […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!